Lupin manufactures pharmaceuticals as a line of business. Globally, APIs, biotechnology products, and generic formulations are all developed and marketed by Lupin Limited. The firm is a worldwide leader in the Anti-TB and Cephalosporins segments and has a substantial presence in the Cardiovascular, Diabetology, Asthma, Paediatrics, and Central Nervous system markets, among others.
Financial Results:
- Lupin Ltd. reported Total Income for Q4FY23 of ₹ 4,430 Crores up from ₹ 3,883 Crore year on year, a rise of 14%.
- Total Expenses for Q4FY23 of ₹ 4,209 Crores up from ₹ 3,984 Crores year on year, rise of 6%.
- Consolidated Net Profit of ₹ 259 Crores, up from a loss of ₹ 850 Crores in the same quarter of the previous year.
- The Earnings per Share is ₹ 5.16, down 62% from ₹ -11.40 in the same quarter of the previous year.